This unique combination of T-cell and NK-cell capabilities exerts a potent and widely MHC -unrestricted anti-tumour cytotoxicity against a broad range of cancer cells.
Cytokine-induced killer (CIK) cells have, as a key feature, a double T-cell and NK cell-like phenotype.
How does Cytokine-induced killer cells affect cancer cells?
1. Cytokine induced killer (CIK) cells have, as a key feature, a double T-cell and NK (Natural killer) cell-like phenotype. This unique combination of T-cell and NK-cell capabilities exerts a potent and widely MHC-unrestricted anti-tumor cytotoxicity against a broad range of cancer cells. What this means is that unlike other immune cells (eg T-Lymphocyte) which can only kill infected and malignant cells that have ‘red flags’ (such as MHC and antibodies) on them, CIK has the ability to identify and kill infected and cancer cells with or without these ‘red flags’. This factor potentiates a quick and an unbiased response by the immune system.
2. CIKs, alone or in combination with other therapies, have proven safe and efficient in clinical practice
3. CIK cells displayed a high cytotoxic potential against a broad range of varying tumor entities. CIK cell treatment has been proven to completely remit tumor burden, prolong survival durations and improve quality of life, even in advanced disease stages.
What is the process to get doctors response in the individuals case?
1. Request the treatment (by phone or in an electronic form) supplemented with your medical information:
- records of medical history,
- latest general clinical and biochemical blood test.
2. Based on these documents, doctors will make an assessment of your health condition and make the decision on the suitability of the therapy.
Why do patients choose Cytokine-induced killer (CIK) cell-based immunotherapy?
CIK therapy in combination with chemotherapy significantly improved survival time and relieving the major side effects of standard treatment options.
CIK cells are a very attractive tool for adoptive immunotherapy approaches against solid tumours and hematological. They can be easily expanded using a straightforward and inexpensive expansion protocol, and are safe as they only require GMP-grade cytokines to obtain very high amounts of cytotoxic cells.
CIK cells have shown promising results in clinical trials, exhibiting a good profile of safety and tolerability due to the almost complete lack of GVHD activity, even in allogeneic settings.